Tobramycin Inhalation Solution USP will treat cystic fibrosis patients with P. aeruginosa
Lupin has launched Tobramycin Inhalation Solution USP in the US market. The solution has received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.
Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).
Comments are closed.